Fust Matthew K 4

What Happened

• Matthew K. Fust, a director of Crinetics Pharmaceuticals (CRNX), received equity awards on 2026-06-18: 5,925 restricted stock units (RSUs) and a derivative award for 9,730 shares (reported as a stock option). Both awards are reported with a $0 per-share transaction price and $0 reported value on the Form 4. These are grants/awards (not open-market purchases or sales) and are typically part of director compensation.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-22 (filed within the normal 2-business-day window for this timing).
• Awards: 5,925 RSUs (acquired, $0.00 per share) and 9,730 derivative shares (option award, $0.00 per share); combined award equals 15,655 shares granted as reported.
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes:
  • RSUs (F1) vest 100% on the earlier of (a) the first anniversary of the grant or (b) the next annual meeting of stockholders, subject to continued board service.
  • Option (F2) vests and becomes exercisable on the earlier of (a) the first anniversary of the grant or (b) the next annual meeting, subject to continued board service.
• No indication in this filing of 10b5-1 plans, tax-withholding share surrender, or immediate sales of awarded shares.

Context

• These are compensation awards (not purchases or sales). RSU grants and options are common for directors and reflect compensation rather than an immediate market bet. The derivative line represents an option-like award—vesting and exercisability are service-based and tied to corporate events per the footnotes.